Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(9):1215–1220. doi: 10.1038/bjc.1997.536

Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma.

R Colomer 1, J Aparicio 1, S Montero 1, C Guzmán 1, L Larrodera 1, H Cortés-Funes 1
PMCID: PMC2228128  PMID: 9365172

Abstract

It has been suggested that angiogenesis and angiogenic factors may be strong predictors of relapse in patients with breast carcinoma. We measured the levels of the angiogenic peptide basic fibroblast growth factor (bFGF) in 140 breast tumour cytosols using an immunoassay. There were no significant differences in bFGF levels between breast non-malignant lesions and primary carcinomas. In 124 cases with primary breast cancer, we observed an association of low bFGF levels (< 400 pg mg[-1]) with increasing tumour size (P = 0.023) and stage of disease (P = 0.002). bFGF levels did not correlate with other variables, including axillary nodes, hormone receptors, cathepsin D and the serum tumour markers CA15.3 and CEA. With a median follow-up of 44.0 months, breast cancer patients with low levels of bFGF had a significantly shorter disease-free survival (DFS) than patients with elevated bFGF (log-rank, P < 0.0001). In a multivariate analysis of DFS, only bFGF, T-stage and histological grade showed statistical significance. In a parallel evaluation of circulating bFGF, we did not observe a correlation between the serum and tissue bFGF levels in the 29 selected cases with matched determinations. Our results indicate that low bFGF levels in breast carcinoma are an independent prognostic indicator of poor prognosis and disease recurrence.

Full text

PDF
1216

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman D. G., Lausen B., Sauerbrei W., Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994 Jun 1;86(11):829–835. doi: 10.1093/jnci/86.11.829. [DOI] [PubMed] [Google Scholar]
  2. Anandappa S. Y., Winstanley J. H., Leinster S., Green B., Rudland P. S., Barraclough R. Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease. Br J Cancer. 1994 Apr;69(4):772–776. doi: 10.1038/bjc.1994.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Davies B. R., Fernig D. G., Barraclough R., Rudland P. S. Effect on tumorigenicity and metastasis of transfection of a diploid benign rat mammary epithelial cell line with DNA corresponding to the mRNA for basic fibroblast growth factor. Int J Cancer. 1996 Jan 3;65(1):104–111. doi: 10.1002/(SICI)1097-0215(19960103)65:1<104::AID-IJC18>3.0.CO;2-G. [DOI] [PubMed] [Google Scholar]
  4. Folkman J., Shing Y. Angiogenesis. J Biol Chem. 1992 Jun 5;267(16):10931–10934. [PubMed] [Google Scholar]
  5. Gasparini G., Harris A. L. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol. 1995 Mar;13(3):765–782. doi: 10.1200/JCO.1995.13.3.765. [DOI] [PubMed] [Google Scholar]
  6. Gomm J. J., Smith J., Ryall G. K., Baillie R., Turnbull L., Coombes R. C. Localization of basic fibroblast growth factor and transforming growth factor beta 1 in the human mammary gland. Cancer Res. 1991 Sep 1;51(17):4685–4692. [PubMed] [Google Scholar]
  7. Guelstein V. I., Tchypysheva T. A., Ermilova V. D., Ljubimov A. V. Myoepithelial and basement membrane antigens in benign and malignant human breast tumors. Int J Cancer. 1993 Jan 21;53(2):269–277. doi: 10.1002/ijc.2910530217. [DOI] [PubMed] [Google Scholar]
  8. Kandel J., Bossy-Wetzel E., Radvanyi F., Klagsbrun M., Folkman J., Hanahan D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell. 1991 Sep 20;66(6):1095–1104. doi: 10.1016/0092-8674(91)90033-u. [DOI] [PubMed] [Google Scholar]
  9. Ke Y., Fernig D. G., Wilkinson M. C., Winstanley J. H., Smith J. A., Rudland P. S., Barraclough R. The expression of basic fibroblast growth factor and its receptor in cell lines derived from normal human mammary gland and a benign mammary lesion. J Cell Sci. 1993 Sep;106(Pt 1):135–143. doi: 10.1242/jcs.106.1.135. [DOI] [PubMed] [Google Scholar]
  10. Luqmani Y. A., Graham M., Coombes R. C. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer. 1992 Aug;66(2):273–280. doi: 10.1038/bjc.1992.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nanus D. M., Schmitz-Dräger B. J., Motzer R. J., Lee A. C., Vlamis V., Cordon-Cardo C., Albino A. P., Reuter V. E. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst. 1993 Oct 6;85(19):1597–1599. doi: 10.1093/jnci/85.19.1597. [DOI] [PubMed] [Google Scholar]
  12. Sliutz G., Tempfer C., Obermair A., Dadak C., Kainz C. Serum evaluation of basic FGF in breast cancer patients. Anticancer Res. 1995 Nov-Dec;15(6B):2675–2677. [PubMed] [Google Scholar]
  13. Takei Y., Kurobe M., Uchida A., Hayashi K. Serum concentrations of basic fibroblast growth factor in breast cancer. Clin Chem. 1994 Oct;40(10):1980–1981. [PubMed] [Google Scholar]
  14. Weidner N., Semple J. P., Welch W. R., Folkman J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991 Jan 3;324(1):1–8. doi: 10.1056/NEJM199101033240101. [DOI] [PubMed] [Google Scholar]
  15. Zimering M. B., Katsumata N., Sato Y., Brandi M. L., Aurbach G. D., Marx S. J., Friesen H. G. Increased basic fibroblast growth factor in plasma from multiple endocrine neoplasia type 1: relation to pituitary tumor. J Clin Endocrinol Metab. 1993 May;76(5):1182–1187. doi: 10.1210/jcem.76.5.8098714. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES